嵌入氧化/碳材料的超分子药物输送系统具有光开关特性,用于高度选择性和有效的化疗
Fasih Bintang Ilhami1, Munasir2, Noto Susanto Gultom3
1Department of Natural Science, Faculty of Mathematics and Natural Science, Universitas Negeri Surabaya, Surabaya 60231, Indonesia.
ACS applied bio materials
|July 9, 2024
概括
研究人员开发了一种新的ZnO/PNS-C纳米凝用于癌症光疗. 这种神经系统针对瘤,并在暴露于光线时产生氧物种,对癌细胞具有高度选择性.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术 纳米技术
- 癌症治疗 癌症治疗
背景情况:
- 光疗是一种有前途的癌症治疗方法.
- 开发用于瘤定位和氧气物种生成的治疗系统仍然具有挑战性.
研究的目的:
- 为了合成一种用于向癌症光疗的新型超分子系统.
- 创建一种能够瘤局部化和反应性氧物种 (ROS) 生产的催眠剂.
主要方法:
- 通过在水溶液中用花生基碳 (PNS-C) 装饰氧化 (ZnO) 来合成球形纳米结构.
- 由此产生的ZnO/PNS-C超分子系统经历了自发的自我组装成纳米凝.
- 进行了体外测试,以评估ROS的产生,稳定性,生物相容性和光毒性.
主要成果:
- ZnO/PNS-C纳米凝表现出稳定性,生物相容性和pH/光敏感性.
- 对ZnO/PNS-C系统的光照射导致了显著的活性氧物种的产生.
- 实验室研究显示,对癌细胞有选择性的光毒性,对正常细胞没有影响.
结论:
- ZnO/PNS-C超分子系统是癌症光疗中的一个有前途的治疗剂.
- 该系统提供了增强的瘤选择性和治疗疗效.
- 对推进向癌症治疗的潜力.
相关概念视频
Carrier-Mediated Transport
1.6K
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
1.6K
Drug Delivery Systems: Different Types
418
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
418
Modified-Release Drug Delivery Systems: Classification
318
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
318
Modified-Release Drug Delivery Systems: Stimuli-Activated
184
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
184
Modified-Release Drug Delivery Systems: Site-Targeted
167
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
167
Site-Targeted Drug Delivery Systems: Polymeric Carriers
165
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
165


